Insights

Growth forecast Revenue momentum and raised full-year guidance to around 6.1 billion DKK in 2026 present a growing demand for Bavarian Nordic vaccines, signaling strong upsell and expansion opportunities across travel health and mpox/chikungunya portfolios with current and potential government contracts.

Strategic partnerships Key collaborations with U.S. government for smallpox and mpox vaccines, Eurofarma for Latin America rights, and CIG Healthcare Partnership for chikungunya content indicate a proven channel strategy and potential for additional regional distribution deals and co-development opportunities.

Executive transition Upcoming leadership change with Tarja Stenvall becoming CEO presents a window to engage early on strategic initiatives, partnerships, and new market expansions aligned with the incoming leadership's priorities.

Global demand drivers Dominant position in smallpox and mpox vaccines coupled with a diverse traveler and endemic disease portfolio positions Bavarian Nordic to pursue regional expansions, government procurement deals, and travel health programs in emerging and established markets.

Financial resilience Significant funding and government support, including a $2.3B US government investment for mpox vaccine development, underpin a stable foundation for joint development programs, manufacturing scale-up collaborations, and long-cycle government contracting opportunities.

Similar companies to Bavarian Nordic

Bavarian Nordic Tech Stack

Bavarian Nordic uses 8 technology products and services including SAP FICO, AutoCAD, Segment, and more. Explore Bavarian Nordic's tech stack below.

Media & News

Bavarian Nordic's Email Address Formats

Bavarian Nordic uses at least 3 email formats:
Bavarian Nordic Email FormatsExamplePercentage
First.Last@bavarian-nordic.comJohn.Doe@bavarian-nordic.com
95%
FLast@bavarian-nordic.comJDoe@bavarian-nordic.com
4%
First.L@bavarian-nordic.comJohn.D@bavarian-nordic.com
1%

Frequently Asked Questions

What is Bavarian Nordic's phone number?

Minus sign iconPlus sign icon
You can contact Bavarian Nordic's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Bavarian Nordic's official website and social media links?

Minus sign iconPlus sign icon
Bavarian Nordic's official website is bavarian-nordic.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Bavarian Nordic generate?

Minus sign iconPlus sign icon
As of October 2026, Bavarian Nordic's annual revenue is estimated to be $500M - $1B.

What is Bavarian Nordic's SIC code and NAICS code?

Minus sign iconPlus sign icon
Bavarian Nordic's SIC code is 2835 - In Vitro and In Vivo Diagnostic Substances and NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does Bavarian Nordic have currently?

Minus sign iconPlus sign icon
As of October 2026, Bavarian Nordic has approximately 1.8K employees across 6 continents, including Europe, North America and South America. Key team members include Cfo: S. S., Chief Operating Officer: R. T. and Chief Marketing Officer Governance & Planning: T. S. P. E. M. A. S. C. O. L. Explore Bavarian Nordic's employee directory with LeadIQ.

What industry does Bavarian Nordic belong to?

Minus sign iconPlus sign icon
Bavarian Nordic operates in the Pharmaceutical Manufacturing industry.

What technology does Bavarian Nordic use?

Minus sign iconPlus sign icon
Bavarian Nordic's tech stack includes SAP FICO, AutoCAD, Segment, Snowflake, Microsoft 365, Microsoft Active Directory, ServiceNow and Screaming Frog SEO Spider.

What is Bavarian Nordic's email format?

Minus sign iconPlus sign icon
Bavarian Nordic's email format typically follows the pattern of First.Last@bavarian-nordic.com. Find more Bavarian Nordic email formats with LeadIQ.

How much funding has Bavarian Nordic raised to date?

Minus sign iconPlus sign icon
As of October 2026, Bavarian Nordic has raised $329M in funding. The last funding round occurred on Oct 03, 2021 for $172M.

When was Bavarian Nordic founded?

Minus sign iconPlus sign icon
Bavarian Nordic was founded in 1994.
Bavarian Nordic logo

Bavarian Nordic

Pharmaceutical ManufacturingHovedstaden, Denmark1001-5000 Employees

Bavarian Nordic is a pharmaceutical manufacturing company based in Copenhagen, Denmark, focused on the development, manufacturing, and commercialization of vaccines, and it maintains the website bavarian-nordic.com. With more than 25 years of experience, it describes itself as a fully integrated vaccine company working across the vaccine value chain. The company positions itself as a global leader in smallpox and mpox vaccines, developed through a long-standing partnership with the U.S. Government to strengthen public health preparedness, and it maintains a portfolio for travelers and endemic diseases. It reports a global workforce of more than 1,400 dedicated staff, with an employee range of 1,001-5,000. In 2026, Bavarian Nordic announced investments in a commercial manufacturing facility to support its production capabilities.

Section iconCompany Overview

Phone number
SIC Code
2835 - In Vitro and In Vivo Diagnostic Substances
NAICS Code
3254 - Pharmaceutical and Medicine Manufacturing
Founded
1994
Employees
1001-5000

Section iconFunding & Financials

  • $329M

    Bavarian Nordic has raised a total of $329M of funding over 4 rounds. Their latest funding round was raised on Oct 03, 2021 in the amount of $172M as a Post IPO Equity.

  • $500M - $1B

    Bavarian Nordic's revenue is estimated to be in the range of $500M - $1B

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.